Jonathan M. Brotchie mostly deals with Parkinson's disease, Neuroscience, Dyskinesia, Levodopa and Dopamine. His Parkinson's disease research incorporates themes from Dopaminergic and Endocrinology. His research integrates issues of Disease, Parkinsonism and Subthalamic nucleus in his study of Neuroscience.
His research in Dyskinesia intersects with topics in Serotonergic and Pharmacology. His biological study spans a wide range of topics, including NMDA receptor, Opioid receptor and Cannabinoid Receptor Agonists. His study in Dopamine is interdisciplinary in nature, drawing from both Degeneration and 5-HT receptor.
His main research concerns Parkinson's disease, Dyskinesia, Neuroscience, Pharmacology and Dopamine. His studies deal with areas such as Dopaminergic and Endocrinology as well as Parkinson's disease. Jonathan M. Brotchie has researched Dyskinesia in several fields, including Levodopa, Parkinsonism and MPTP.
Jonathan M. Brotchie studies Neuroscience, focusing on Basal ganglia in particular. His Pharmacology study combines topics from a wide range of disciplines, such as Receptor, Antagonist and Dihydroxyphenylalanine. His Dopamine research incorporates themes from NMDA receptor and Opioid peptide.
The scientist’s investigation covers issues in Parkinson's disease, Pharmacology, Neuroscience, Dyskinesia and Dopaminergic. The Parkinson's disease study combines topics in areas such as Dopamine and Parkinsonism. His Pharmacology research integrates issues from Peripheral blood mononuclear cell, Potency, Kinase and LRRK2.
His Neuroscience research is multidisciplinary, relying on both Pathophysiology and Disease. The various areas that Jonathan M. Brotchie examines in his Dyskinesia study include Levodopa, Cognition and MPTP. Endocrinology and Internal medicine are the main topics of his Dopaminergic study.
Jonathan M. Brotchie spends much of his time researching Parkinson's disease, Dopaminergic, Neuroscience, Dopamine and Pharmacology. His Parkinson's disease study frequently links to other fields, such as Neurodegeneration. His Neuroscience study frequently links to related topics such as Disease.
In his work, Anatomy and Nigrostriatal pathway is strongly intertwined with Macaque, which is a subfield of Dopamine. His Pharmacology research incorporates elements of Neurotoxicity, Trehalose, Dyskinesia, Neurochemical and Reuptake inhibitor. His research investigates the connection with Dyskinesia and areas like MPTP which intersect with concerns in Receptor antagonist.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
Erwan Bezard;Erwan Bezard;Sandra Dovero;Caroline Prunier;Paula Ravenscroft.
The Journal of Neuroscience (2001)
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Erwan Bezard;Jonathan M. Brotchie;Christian E. Gross.
Nature Reviews Neuroscience (2001)
Giovanni Fabbrini;Jonathan M. Brotchie;Francisco Grandas;Masahiro Nomoto.
Movement Disorders (2007)
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
Erwan Bezard;Christian E. Gross;Jonathan M. Brotchie.
Trends in Neurosciences (2003)
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Vincenzo Di Marzo;Michael P. Hill;Tiziana Bisogno;Alan R. Crossman.
The FASEB Journal (2000)
Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H V Schapira;Erwan Bezard;Jonathan Brotchie;Frédéric Calon.
Nature Reviews Drug Discovery (2006)
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
K.A. Sieradzan;S.H. Fox;M. Hill;J.P.R. Dick.
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Philippe Huot;Tom H. Johnston;James B. Koprich;Susan H. Fox.
Pharmacological Reviews (2013)
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Jonathan M. Brotchie;Ian J. Mitchell;Michael A. Sambrook;Alan R. Crossman.
Movement Disorders (1991)
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Brian Henry;Alan R. Crossman;Jonathan M. Brotchie.
Experimental Neurology (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: